The CEO has brought all these clinical trials through to good results, spending very little money. One need only look at other small biotechs which have spent many times IPIX's expenditures and have either not even gotten a single drug to a clinical trial, or have gotten only one clinical trial as far as IPIX has gotten five.

What a waste of time to bash IPIX on this board, with its knowledgeable investors.